Suven Life Sciences Limited
SUVEN
Rank in Stocks
#10558
Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical... Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical enterprise dedicated to the identification, progression, and commercialization of innovative therapeutic solutions. Its primary focus lies in addressing neurodegenerative conditions across key markets including India, the United States, Europe, and other international territories. The company's core activities revolve around the discovery and subsequent development of new chemical entities (NCEs) specifically targeting disorders of the central nervous system (CNS). Among its promising pipeline assets are SUVN-502, intended for Alzheimer's disease and associated neuropsychiatric manifestations; SUVN-G3031, a potent and selective inverse agonist of the histamine H3 receptor, aimed at sleep and cognitive impairments; and SUVN-911, a novel, potent, and selective a4Γ2 nicotinic acetylcholine receptor antagonist designed to alleviate depressive disorders. Further advancing its portfolio, Suven is also working on SUVN-D4010, a potent, selective, orally bioavailable, and brain-penetrant partial agonist of the 5-HT4 receptor for cognitive dysfunctions; SUVN-I6107, addressing cognitive issues and schizophrenia; SUVN-M8036 for various psychiatric ailments; and SUVN-D1044, targeting gastrointestinal conditions. Established in 1989, the company is based in Hyderabad, India. It adopted its current name, Suven Life Sciences Limited, in 2003, having previously operated as Suven Pharmaceuticals Pvt. Ltd. Jasti Property and Equity Holdings Private Limited holds a controlling interest in Suven Life Sciences Limited, making it a subsidiary.
Share Price
$2.98
Last synced: 2026-11-09
Market Cap
$679.52M
Change (1 day)
6.28%
Change (1 year)
44.77%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Suven Life Sciences Limited (SUVEN)
Category
Healthcare
Operating Margin for Suven Life Sciences Limited (SUVEN)
Operating Margin as of November 2026 TTM: -4,228.11%
According to Suven Life Sciences Limited's latest financial reports, its current operating margin (TTM) is -4,228.11%. At the end of 2025 the company had an operating margin of -2,578.13%.
Operating Margin history for Suven Life Sciences Limited from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -4,228.11% | 64.00% |
| 2025 | -2,578.13% | 145.92% |
| 2024 | -1,048.35% | 7.60% |
| 2023 | -974.32% | -8.57% |
| 2022 | -1,065.63% | 71.25% |
| 2021 | -622.28% | -24.92% |
| 2020 | -828.78% | -3,960.18% |
| 2019 | 21.47% | -25.76% |
| 2018 | 28.92% | 54.24% |
| 2017 | 18.75% | 11.94% |
| 2016 | 16.75% | -40.98% |
| 2015 | 28.38% | -31.10% |
| 2014 | 41.19% | 134.43% |
| 2013 | 17.57% | 88.32% |
| 2012 | 9.33% | 45.33% |
| 2011 | 6.42% | -7.36% |
| 2010 | 6.93% | -46.90% |
| 2009 | 13.05% | 88.31% |
| 2008 | 6.93% | -36.48% |
| 2007 | 10.91% | 34.03% |
| 2006 | 8.14% | -3.10% |
| 2005 | 8.40% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -100.00% |
DE
|
|
| 19.68% | -100.00% |
DE
|
|
| 13.26% | -100.00% |
JP
|
|
| 17.08% | -100.00% |
CH
|
|
| 14.92% | -100.00% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Suven Life Sciences Limited's operating margin
What is Suven Life Sciences Limited's operating margin?
Suven Life Sciences Limited's operating margin is -4,228.11%, as of Nov 2026.
What was Suven Life Sciences Limited's operating margin in 2025?
In 2025, Suven Life Sciences Limited's operating margin was -2,578.13%, compared with -1,048.35% in 2024.
How has Suven Life Sciences Limited's operating margin changed since 2020?
From 2020 to 2025, Suven Life Sciences Limited's operating margin was highest in 2021 (-622.28%) and lowest in 2025 (-2,578.13%).
How does Suven Life Sciences Limited's operating margin compare with similar companies?
Suven Life Sciences Limited's operating margin (-4,228.11%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.